The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical implication of using up both fluoropyrimidine (FU) and paclitaxel (PTX) in patients with severe peritoneal metastases (SPM) of gastric cancer (GC).
 
Hiroyuki Arai
No Relationships to Disclose
 
Eisuke Inoue
Consulting or Advisory Role - Nippon Tect Systems; Pfizer
Speakers' Bureau - Bristol-Myers Squibb Japan
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Hiroki Hara
No Relationships to Disclose
 
Tomohiro Nisina
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Kohei Shitara
No Relationships to Disclose
 
Katsunori Shinozaki
Honoraria - Asahi Kasei; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck; Mochida Pharmaceutical Co. Ltd.; Nihonkayaku; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda
 
Shinichiro Nakamura
No Relationships to Disclose
 
Ichinosuke Hyodo
Honoraria - Asahi Kasei; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Asahi Kasei
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Kei Muro
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst)
 
Mitsuru Sasako
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Lilly Japan; Merck; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Olympus
 
Masanori Terashima
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)
 
Takako Eguchi Nakajima
Honoraria - Bayer; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Daiichi Sankyo; EPS Corporation; Kyowa Hakko Kirin; Lilly Japan; MERCK SERONO; MSD; Nippon Kayaku; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Research Funding - Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; ICON Clinical Research; Japan Clinical Research Operations; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; PAREXEL; PAREXEL; Sanofi; Taiho Pharmaceutical; Takeda